Michael Drosch

JPT Peptide Technologies, BioNTech SE company, is an innovative research and development partner for peptide-based projects in immunotherapy, proteomics, and drug discovery. •Project Management: End-to-end strategic planning for new product launch; e.g. managed licensing projects for cell therapy products starting from strategic planning, negotiation, contract execution to product launch •Alliance Management and contract governance during all phases •Identification of business partners and initiation of value-creating collaborations in the immunotherapy area •Sales: Customer acquisition and retention especially immunotherapy in the field within EU, representation of the company at scientific conferences and meetings •Scientific support for peptidic immunotherapy products (CAR-T development, adoptive cell transfer, peptide vaccination, dentritic cell priming, clinical immunomonitoring) •Planning and execution of internal strategy workshops

•Authorized officer and primary person for setting up a new subsidiary of an US company in Germany 
 •Built up a new lab infrastructure (safety level S1) and team for production of rabbit MAbs within 6 month •Customer acquisition; lead in negotiation with pharmaceutical and diagnostic companies in EU •Negotiation and execution of service agreements agreements with partners •Increasing companies visibility e.g. by creating a web site and corporate design. Representing the company to external partners, politics and public. Participating in an active scientific network such as DiagnostikNet Berlin •Acquiring permit to conduct genetic engineering operations. Being project leader for genetic engineering and taking care of safety tasks •Hiring and supervising lab personnel , leading and managing a team of three people
 •Pursuing administrative activities such as taxing, accounting, sales Expertise: Antibody development, business development, bookkeeping, accounting, sales, leadership of employees

•Key contact for Bayer for a European Collaboration Network (CanDo) for isolation and analysis of Circulating Tumor Cells (CTCs) 
 •Comparison of of different technology platforms for isolation of circulating tumor cells

•Isolation and analysis of circulating tumor cells from human samples; comparison and optimization of antibody dependent and independent methods for cellular analysis of body fluids. •Supervision of technicians and master students Key techniques: (Immuno-)cytology, single cell manipulation, immuno-histochemistry, FISH analysis, flow cytometry, automated microscopy. Isolation of circulating tumor cells by size, positve and negative enrichment methods (IsoFlux, ISET, MACS, CellCollector..) Expertise: Support and communications with clinical and business collaboration partners.

•Education and teaching of technicians in histology, hematology, physiology and general biology; •Mentoring and participation in evaluation juries, strengthening of interpersonal and communication/ presentation skills. Giving appraisal feedback to trainees. Expertise: Feedback methods, models of communication

Development of a rodent model for uterine fibroids; identification of CD24 positive precursor cells as pathogenic factor in fibroid development Key techniques: In vivo/vitro pharmacology; in vivo tumor models; fluorescence assisted cell sorting; tumor derived cell culture; histology/IHC

•Investigating Induction of senescence by the microtubule-stabilizing sagopilon epothilone. •Key Techniques: In vivo/vitro pharmacology; live and confocal microscopy; PCR; setting up an optical assay for senescence

Techniques: Biological assays for metastasis and invasion; cellular biology

Establishing assays for quantification of radiation induced DNA damage.

Dr. rer. nat. awarded from University of Bremen based on a cumulative thesis with two peer-reviewed publications